# US 2004/0018569 A1 · Proteins involved in cytoadhesion of plasmodium falciparum ring-stage-infected erythrocytes, antibodies which bind to the proteins, and methods for detecting infection, stage of infection and vaccines for protecting against infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018569 A1
- Document ID: US20040018569A1
- Status: Published application
- Kind: A1
- Application number: 10/305,956
- Filed: 2002-11-29
- Published: 2004-01-29
- Earliest claimed: 2000-05-31
- Assignees: Institut Pasteur; Centre National De La Recherche Scientifique
- Inventors: Juerg Gysin; Bruno Pouvelle; Artur Scherf; Pierre Buffet
- Web page: https://patentgrep.com/patent/US20040018569A1

## CPC

- C07K 14/445: Plasmodium
- A61P 33/06: Antimalarials
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/505: {comprising antibodies}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides the RSP-1 and RSP-2 proteins which are involved in the cytoadheion of P. falciparum during ring-stage infection of erythrocytes, antibodies which bind to the proteins, methods of screening for a P. falciparum infection, methods of determining the infective stage of P. falciparum and vaccines for protecting individuals from Plasmodium sp. infections.

## Claims

### Claim 1

An isolated protein which mediates Plasmodium falciparum ring-stage adhesion to endothelial cells and is approximately 200 kilodaltons in size as determined by SDS-polyacrylamide gel electrophoresis.

### Claim 2

An isolated protein which mediates Plasmodium falciparum ring-stage adhesion to endothelial cells and is approximately 40 kilodaltons in size as determined by SDS-polyacrylamide gel electrophoresis.

### Claim 3 (depends on 1, 2)

An antibody which binds to the isolated protein of claim 1 or 2.

### Claim 4 (depends on 3)

The antibody of claim 3 which is a monoclonal antibody.

### Claim 5 (depends on 4)

The antibody of claim 4, which is a polyclonal antibody.

### Claim 6 (depends on 3, 4, 5)

A method of detecting the presence of a Plasmodium species in a sample comprising:
contacting said sample with an antibody according to one of claims 3 to 5; and
identifyig an interaction between the antibody and the Plasmodium species in said sample, wherein said interaction indicates the presence of the Plasmodium species.

### Claim 7 (depends on 6)

The method of claim 6, wherein said Plasmodium species is Plasmodium falciparum.

### Claim 8 (depends on 6)

The method of claim 6, wherein said antibody is coupled to a detectable moiety.

### Claim 9 (depends on 6)

The method of claim 6, wherein said sample is obtained from a human patient suspected of having malaria.

### Claim 10 (depends on 1, 2)

A method of detecting the presence of a Plasmodium antibody in a sample comprising:
contacting said sample with the isolated protein of claim 1 or claim 2; and
identifying an interaction between the protein and the Plasmodium antibody in said sample, wherein said interaction indicates the presence of the Plasmodium.

### Claim 11 (depends on 10)

The method of claim 10, wherein said Plasmodium is Plasmodium falciparum.

### Claim 12 (depends on 10)

The method of claim 10, wherein said protein is coupled to a detectable moiety.

### Claim 13 (depends on 10)

The method of claim 10, wherein said sample is obtained from a human patient suspected of having malaria.

### Claim 14 (depends on 3, 4, 5)

A method of diagnosing the Plasmodium falciparum blood-stage cycle in an individual suspected of being infected with Plasmodium falciparum comprising:
obtaining a biological sample from said individual;
contacting said sample with an antibody according to one of claims 3 to 5; and
identifying an interaction between the antibody and an antigen in said sample, wherein said interaction indicates a ring-stage infection.

### Claim 15 (depends on 1, 2)

A method of diagnosing the Plasinodium falciparum blood-stage cycle in an individual suspected of being infected with Plasmodium falciparum comprising:
obtaining a biological sample from said individual;
contacting said sample with the protein of claims 1 or 2; and
identifying an interaction between the protein and an antibody in said sample, wherein said interaction indicates a ring-stage infection.

### Claim 16

A composition comprising at least one of the isolated proteins RSP-1 and RSP-2 and a pharmaceutical acceptable carrier.

### Claim 17 (depends on 16)

The composition of claim 16, which is an immunogenic composition.

### Claim 18 (depends on 16)

The composition of claim 16, which is a vaccine.

### Claim 19

Composition comprising at least one of the isolated proteins RSP-1 and RSP-2 in an amount sufficient to induce an immune response, for protecting an individual against a Plasmodium falciparum infection in said individual.

### Claim 20 (depends on 19)

Composition of claim 19, which further comprises an adjuvant.

### Claim 21 (depends on 19)

The composition of claim 19, the administration of which is performed one or more times.

### Claim 22

Hybridoma cell named Pf 26G1/B4 deposited at the CNCM on Feb. 23, 2001 under accession number I-2635.
